{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:56:50Z","timestamp":1780977410345,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":917,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1093\/annonc\/mdx134","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T21:26:45Z","timestamp":1490390805000},"page":"912-913","source":"Crossref","is-referenced-by-count":38,"title":["Intratumoral heterogeneity in gastric cancer: a new challenge to face"],"prefix":"10.1016","volume":"28","author":[{"given":"M.","family":"Alsina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx134_bb0010","series-title":"Cancer Incidence, Mortality and Prevalence Worldwide","article-title":"Globocan 2002. IARC CancerBase No. 5","author":"Ferlay","year":"2004"},{"key":"10.1093\/annonc\/mdx134_bb0015","unstructured":"I Gullo , FCarneiro, COliveira, GAlmeida . Heterogeneity in gastric cancer: from pure morphology to molecular classifications. Pathobiology; in press."},{"key":"10.1093\/annonc\/mdx134_bb0020","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx134_bb0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx134_bb0030","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx134_bb0035","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","author":"Burrell","year":"2013","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdx134_bb0040","doi-asserted-by":"crossref","first-page":"7.","DOI":"10.1186\/s12876-015-0231-4","article-title":"Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer","volume":"15","author":"Stahl","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"10.1093\/annonc\/mdx134_bb0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC-A randomized phase III trial","volume":"34","author":"Hecht","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx134_bb0050","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN\u2013a randomized, phase III study","volume":"32","author":"Satoh","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 4S","key":"10.1093\/annonc\/mdx134_bb0055","article-title":"A randomized, open-label, multicenter, adaptive phase 2\/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma","volume":"34","author":"Kang","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx134_bb0060","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.ejca.2012.10.018","article-title":"Clinical significance of intratumoral HER2 heterogeneity in gastric cancer","volume":"49","author":"Lee","year":"2013","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdx134_bb0065","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/annonc\/mdw442","article-title":"Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment","volume":"28","author":"An","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx134_bb0070","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-15-1246","article-title":"High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial","volume":"6","author":"Pearson","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdx134_bb0075","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","article-title":"Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial","volume":"14","author":"Lordick","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx134_bb0080","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","volume":"14","author":"Waddell","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx134_bb0085","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","article-title":"Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study","volume":"31","author":"Ohtsu","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx134_bb0090","article-title":"Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial","author":"Shah","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1093\/annonc\/mdx134_bb0095","doi-asserted-by":"crossref","first-page":"4014.","DOI":"10.1200\/jco.2015.33.15_suppl.4014","article-title":"A randomized, open-label phase II study of AZD4547 (AZD) versus paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with fibroblast growth factor receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study [abstract]","volume":"33","author":"Bang","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx134_bb0100","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/j.gastro.2013.05.010","article-title":"Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil","volume":"145","author":"Lei","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1093\/annonc\/mdx134_bb0105","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"TCGA","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdx134_bb0110","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdx134_bb0115","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/modpathol.2016.55","article-title":"A protein and mRNA expression-based classification of gastric cancer","volume":"29","author":"Setia","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/mdx134_bb0120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/PAS.0000000000000756","article-title":"High-throughput protein and mRNA expression-based classification of gastric cancers can identify clinically distinct subtypes, concordant with recent molecular classifications","volume":"41","author":"Ahn","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1093\/annonc\/mdx134_bb0125","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/annonc\/mdx047","article-title":"Epstein\u2013Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations","volume":"28","author":"B\u00f6ger","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx134_bb0130","doi-asserted-by":"crossref","first-page":"771","DOI":"10.21037\/jgo.2016.08.06","article-title":"The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1","volume":"7","author":"Jin","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdx134_bb0135","doi-asserted-by":"crossref","first-page":"e000009","DOI":"10.1136\/esmoopen-2015-000009","article-title":"NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer","volume":"1","author":"Das","year":"2016","journal-title":"ESMO Open"},{"key":"10.1093\/annonc\/mdx134_bb0140","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/5\/912\/13942928\/mdx134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:16:22Z","timestamp":1624695382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419320381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0923753419320381"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx134","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}